UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2971-2979

2005

Volltextzugriff (PDF)

Grain boundary chromium depletion in austenitic alloys

Journal of materials science, 2010-11, Vol.45 (21), p.5872-5882

2010

Volltextzugriff (PDF)

Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia

The Lancet (British edition), 2014-02, Vol.383, p.S66-S66

2014

Volltextzugriff (PDF)

Minimal residual disease is an independent predictor for 10-year survival in CLL

Blood, 2016-12, Vol.128 (24), p.2770-2773

2016

Volltextzugriff (PDF)

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Journal of clinical oncology, 2014-04, Vol.32 (12), p.1236-1241

2014

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2005-11, Vol.23 (31), p.8123-8124

Moreton, Paul

2005

Volltextzugriff (PDF)

At risk of exclusion? : a study of the experiences of, and support provided for, ten young people aged 14-16 in two large, urban secondary schools

Moreton, Paul

2018

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7241-7242

Moreton, Paul

2005

Volltextzugriff (PDF)

Alemtuzumab therapy in B-cell lymphoproliferative disorders

Seminars in oncology, 2003-08, Vol.30 (4), p.493-501

2003

Volltextzugriff (PDF)

The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research

British journal of haematology, 2010-03, Vol.148 (5), p.739-753

2010

Volltextzugriff (PDF)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Blood, 2004-08, Vol.104 (4), p.948-955

2004

Volltextzugriff (PDF)

Simultaneous acute myeloid leukaemia and de novo acute hepatitis B: A novel management strategy

Leukemia research, 2011-06, Vol.35 (6), p.e67-e68

2011

Volltextzugriff (PDF)

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

British journal of haematology, 2009-01, Vol.144 (1), p.78-85

2009

Volltextzugriff (PDF)

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Blood, 2016-12, Vol.128 (22), p.5479-5479

2016

Volltextzugriff (PDF)

B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle

British journal of haematology, 2007-11, Vol.139 (4), p.600-604

2007

Volltextzugriff (PDF)

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Blood, 2012-11, Vol.120 (21), p.889-889

2012

Volltextzugriff (PDF)

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Blood, 2004-03, Vol.103 (6), p.2027-2031

2004

Volltextzugriff (PDF)

Alemtuzumab therapy in B-cell lymphoproliferative disorders: Monoclonal Antibody Therapy for Hematologic Malignancies

Seminars in oncology, 2003, Vol.30 (4), p.493-501

2003

Volltextzugriff (PDF)

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Blood, 2010-11, Vol.116 (21), p.922-922

2010

Volltextzugriff (PDF)

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Blood, 2010-11, Vol.116 (21), p.697-697

2010

Volltextzugriff (PDF)

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL)

Blood, 2009-11, Vol.114 (22), p.3428-3428

2009

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(55)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(62)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Grain boundary chromium depletion in austenitic alloys

Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia

Minimal residual disease is an independent predictor for 10-year survival in CLL

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

In Reply

At risk of exclusion? : a study of the experiences of, and support provided for, ten young people aged 14-16 in two large, urban secondary schools

In Reply

Alemtuzumab therapy in B-cell lymphoproliferative disorders

The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Simultaneous acute myeloid leukaemia and de novo acute hepatitis B: A novel management strategy

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Alemtuzumab therapy in B-cell lymphoproliferative disorders: Monoclonal Antibody Therapy for Hematologic Malignancies

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL)

Suchergebnisse filtern